Trinity Biotech PLC
Company Profile
Business description
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Contact
IDA Business Park
Bray, County Wicklow
DublinA98 H5C8
IRLT: +353 12769800
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
401
Stocks News & Analysis
stocks
WiseTech result disappoints, but the future looks bright
stocks
WOW earnings: Woolworths losing market share, but will catch up to Coles
stocks
Chart of the Week: Largest share price falls during earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,241.10 | 0.50 | -0.01% |
CAC 40 | 7,762.60 | 18.67 | 0.24% |
DAX 40 | 24,039.92 | 6.29 | -0.03% |
Dow JONES (US) | 45,573.14 | 7.91 | 0.02% |
FTSE 100 | 9,216.82 | 38.68 | -0.42% |
HKSE | 24,998.82 | 202.94 | -0.81% |
NASDAQ | 21,700.56 | 110.42 | 0.51% |
Nikkei 225 | 42,828.79 | 308.52 | 0.73% |
NZX 50 Index | 12,903.08 | 41.24 | 0.32% |
S&P 500 | 6,495.76 | 14.36 | 0.22% |
S&P/ASX 200 | 8,980.00 | 9.50 | 0.11% |
SSE Composite Index | 3,843.60 | 43.25 | 1.14% |